Solan Headlines

Non-Alcoholic Steatohepatitis (NASH) Market to Witness Increasing Growth $21,478 Million at CAGR of 58.4% In 2025 | Allied Market Research

 Breaking News
  • No posts were found

Non-Alcoholic Steatohepatitis (NASH) Market to Witness Increasing Growth $21,478 Million at CAGR of 58.4% In 2025 | Allied Market Research

September 03
15:42 2019
Non-Alcoholic Steatohepatitis (NASH) Market to Witness Increasing Growth $21,478 Million at CAGR of 58.4% In 2025 | Allied Market Research

Non-Alcoholic Steatohepatitis (NASH) Market
high unmet needs and expected launch of strong pipeline drugs would play a major role in the growth of the NASH market. Furthermore, growth in prevalence of NASH and rise in demand for ideal NASH therapeutics are expected to boost the demand for NASH therapeutics in the coming years.

According to a new report published by Allied Market Research, titled, “Non-Alcoholic Steatohepatitis (NASH) Marketby Drug Type and Sales Channel: Global Opportunity Analysis and Industry Forecast, 20212025,” the global non-alcoholic steatohepatitis (NASH) market was valued at $1,179 million in 2017, and is expected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

At present, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to manage patients with NASH. Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/224

Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world. However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.

Get a purchase enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/224

North America accounted approximately one half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. Major factors that driving the market growth in North America are, early diagnosis of the disease, higher prevalence of disease, and strong presence of pipeline drugs. On the other hand, Asia-Pacific is expected to experience the highest CAGR of 62.62% during the forecast period primarily due to growth in prevalence of NASH along with the increase in prevalence of diabetes & obesity and rise in awareness of NASH among the patients. Furthermore, growth in number of R&D activities, development in diagnostic technologies, and increase in healthcare spending is expected to drive the NASH market in Asia-Pacific region.

Leading market players:-

Allergan plc. (Tobira Therapeutics), Cadila Healthcare Limited, Conatus Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd, Gemphire Therapeutics Inc., Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novartis International AG, and Shire Plc.

 

Similar Reports:

Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class – Global Opportunity Analysis and Industry Forecast, 2017-2023

World Potential Analysis of Ebola drug and Vaccines Market – Opportunities and Forecasts, 2020

 

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Media Contact
Company Name: Allied Market Research
Contact Person: David Correa
Email: Send Email
Phone: +1-800-792-5285
Address:5933 NE Win Sivers Drive #205
City: Portland
State: OR 97220
Country: United States
Website: www.alliedmarketresearch.com/nonalcoholic-steatohepatitis-NASH-market

Related Articles